Westfield Capital Management Co. LP Trims Stock Holdings in Sanofi (NASDAQ:SNY)

Westfield Capital Management Co. LP decreased its holdings in shares of Sanofi (NASDAQ:SNY) by 6.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 109,867 shares of the company’s stock after selling 8,037 shares during the quarter. Westfield Capital Management Co. LP’s holdings in Sanofi were worth $6,332,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the stock. Boston Partners raised its stake in shares of Sanofi by 0.3% during the 1st quarter. Boston Partners now owns 13,066,403 shares of the company’s stock valued at $635,280,000 after purchasing an additional 33,657 shares during the period. Bank of New York Mellon Corp increased its position in shares of Sanofi by 19.0% during the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after buying an additional 1,370,232 shares during the period. Barrow Hanley Mewhinney & Strauss LLC increased its position in shares of Sanofi by 113.8% during the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after buying an additional 3,164,092 shares during the period. Envestnet Asset Management Inc. lifted its holdings in shares of Sanofi by 8.2% in the second quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock worth $157,803,000 after buying an additional 246,224 shares in the last quarter. Finally, Federated Hermes Inc. boosted its position in shares of Sanofi by 26.5% in the second quarter. Federated Hermes Inc. now owns 3,214,141 shares of the company’s stock valued at $155,950,000 after acquiring an additional 673,172 shares during the period. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Sanofi Stock Up 0.6 %

SNY stock opened at $48.28 on Monday. Sanofi has a 1-year low of $45.22 and a 1-year high of $58.97. The stock has a market cap of $122.53 billion, a price-to-earnings ratio of 24.63, a price-to-earnings-growth ratio of 1.22 and a beta of 0.61. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The company’s 50 day moving average is $53.70 and its 200 day moving average is $52.18.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The firm had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. During the same quarter last year, the company posted $2.55 EPS. The business’s quarterly revenue was up 12.3% on a year-over-year basis. Sell-side analysts predict that Sanofi will post 4.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Citigroup raised shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.